No Data
Nephron Initiates Quest Diagnostics(DGX.US) With Hold Rating, Announces Target Price $184
Under Trump's tariff threats, a new "landscape" in the USA: stockpiling medicine!
According to several Company Executives in the Pharmaceutical industry and Logistics companies, due to concerns that the reciprocal tariffs announced by President Trump on April 2 may involve Pharmaceutical products from Europe, some Pharmaceutical companies are taking unusual measures to transport more drugs to the USA via Air Transportation; Two Pharmaceutical companies headquartered in Europe stated to the media this week that they have transported as many Pharmaceutical products to the USA as possible in recent weeks, and they have also learned that other Pharmaceutical companies are taking similar actions.
Nephron Research Downgrades Quest Diagnostics to Hold From Buy, $184 Price Target
Truist Financial Maintains Quest Diagnostics(DGX.US) With Hold Rating, Announces Target Price $182
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN), Quest Diagnostics (DGX) and Belite Bio, Inc. ADR (BLTE)
Hospital Stocks Are Ready to Rebound, Deutsche Bank Says
